Related Experiment Video
Updated: Aug 12, 2026

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
Published on: October 15, 2010
The total vascular burden, peripheral and coronary: vasodilator effects of nifedipine
1Department of Medicine, University of Cape Town Observatory, South Africa.
Insights
Nifedipine effectively reduces vascular burden in cardiovascular diseases, improving left ventricular function and decreasing myocardial ischemia risk. Careful patient selection is crucial for optimal outcomes.
Area of Science:
- Cardiology
- Pharmacology
Background:
- The total vascular burden on the heart includes systemic, pulmonary, and coronary vascular resistance, significantly influenced by hypertension and left ventricular hypertrophy.
- These factors can impair left ventricular function and predispose to myocardial ischemia.
Purpose of the Study:
- To evaluate the effects of nifedipine on vascular burden and left ventricular function in various cardiovascular conditions.
- To assess the safety and efficacy of nifedipine in patients with hypertension, acute myocardial infarction, and congestive heart failure.
Main Methods:
- Review of studies investigating nifedipine's impact on vascular resistance, left ventricular ejection fraction, and diastolic filling rates.
- Analysis of clinical outcomes in patients with hypertension, acute myocardial infarction, congestive heart failure, and angina treated with nifedipine, alone or in combination with beta-blockers.
Main Results:
- Nifedipine increased left ventricular ejection fraction and diastolic filling rate in hypertensive patients with cardiomegaly.
- In acute myocardial infarction, nifedipine improved the left ventricular function curve with decreased pulmonary wedge pressure and increased cardiac output.
- Low-dose nifedipine demonstrated beneficial effects in congestive heart failure by reducing afterload, with rare adverse events reported.
Conclusions:
- Nifedipine administration, when appropriate, reduces the total vascular burden in diverse cardiovascular diseases.
- This reduction in vascular burden leads to improved left ventricular function and a decreased risk of myocardial ischemia.
- Combination therapy with beta-blockers and nifedipine shows promise for angina, hypertension, and hypertrophic cardiomyopathy.
Abstract:
While the total ischemic burden on the left ventricle represents the combined effects of both symptomatic and asymptomatic myocardial ischemia, the total vascular burden has many components including an increased systemic peripheral vascular resistance, an increased pulmonary vascular resistance, and an increased coronary vascular resistance. These factors may all influence ventricular function. Hypertension contributes significantly to the vascular burden, especially when combined with left ventricular hypertrophy, which predisposes to ischemia by multiple mechanisms. In patients with hypertension and cardiomegaly, sublingual nifedipine has been shown to increase left ventricular (LV) ejection fraction and the average diastolic filling rate. In the presence of acute myocardial infarction, nifedipine moves the LV function curve onto a better Frank-Starling relationship as pulmonary wedge pressure falls or stays the same and cardiac output rises. However, because of the delicate balance between myocardial perfusion and the benefits of afterload reduction, including improved remodelling, nifedipine should be given only to selected patients. In congestive heart failure, low-dose nifedipine reduces the afterload and has been shown to have beneficial effects in the majority of patients. Two specific adverse outcomes in only two patients have been reported, one with initial hypotension and one given high-dose nifedipine. Combination nifedipine-beta blocker therapy has been shown to be favorable in the treatment of all varieties of angina, hypertension, and hypertrophic cardiomyopathy. Therefore, when administered appropriately, nifedipine reduces the total vascular burden on the heart in a variety of cardiovascular diseases, with consequent improvement in LV function and a diminished threat of potential myocardial ischemia.
More Related Videos
Related Concept Videos
Antihypertensive Drugs: Action of Calcium Channel Blockers
Antihypertensive Drugs: Vasodilators
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Heart Failure Drugs: β-Blockers
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...

